{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:34:56Z","timestamp":1792805696211,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.prp.2023.154632","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T20:53:01Z","timestamp":1687207981000},"page":"154632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["New immunotherapeutic approaches for cancer treatment"],"prefix":"10.1016","volume":"248","author":[{"given":"Amin","family":"Kamrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Shomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad Ahmadian","family":"Heris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mohammadinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Sadeghvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Ghahremanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.prp.2023.154632_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for cancer: a trigger for metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"issue":"9","key":"10.1016\/j.prp.2023.154632_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154632_bib5","first-page":"8052212","article-title":"Recent advances and next breakthrough in immunotherapy for cancer treatment","volume":"2022","author":"Yang","year":"2022","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.prp.2023.154632_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172783","article-title":"Anti-androgen hormonal therapy for cancer and other diseases","volume":"866","author":"Student","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.prp.2023.154632_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"10","key":"10.1016\/j.prp.2023.154632_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrc3798","article-title":"Stem cell-based therapies for cancer treatment: separating hope from hype","volume":"14","author":"Stuckey","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume":"20","author":"Ansari","year":"2022","journal-title":"Cell Commun. Signal.: CCS"},{"issue":"7","key":"10.1016\/j.prp.2023.154632_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s00262-020-02831-1","article-title":"Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma","volume":"70","author":"Leenen","year":"2021","journal-title":"Cancer Immunol., Immunother.: CII"},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2023.154632_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.tibtech.2019.12.009","article-title":"Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy","volume":"38","author":"Fritsche","year":"2020","journal-title":"Trends Biotechnol."},{"issue":"11","key":"10.1016\/j.prp.2023.154632_bib14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/iub.2558","article-title":"PD-1\/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity","volume":"73","author":"Hosseinzadeh","year":"2021","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"6230","key":"10.1016\/j.prp.2023.154632_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12766","article-title":"Immune checkpoint inhibitors: The linchpins of modern immunotherapy","volume":"290","author":"Wilky","year":"2019","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.prp.2023.154632_bib18","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.prp.2023.154632_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"6230","key":"10.1016\/j.prp.2023.154632_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.prp.2023.154632_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/annrheumdis-2017-212061","article-title":"The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy","volume":"77","author":"Calabrese","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7150\/jca.17144","article-title":"Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor","volume":"8","author":"Guo","year":"2017","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma","volume":"73","author":"Ivashko","year":"2016","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.prp.2023.154632_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211066147","article-title":"Brief overview: Cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again","volume":"14","author":"Davis","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"29","key":"10.1016\/j.prp.2023.154632_bib26","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.2217\/fon-2021-0598","article-title":"Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer","volume":"17","author":"Oaknin","year":"2021","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1358\/dot.2017.53.4.2589163","article-title":"Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers","volume":"53","author":"Krishnamurthy","year":"2017","journal-title":"Drugs Today (Barc., Spain.: 1998)"},{"issue":"2","key":"10.1016\/j.prp.2023.154632_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/cr.2016.102","article-title":"Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.prp.2023.154632_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L) 1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"da Silva","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.prp.2023.154632_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2023.154632_bib32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/2326-6066.CIR-15-0190","article-title":"T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition.","volume":"3","author":"Houot","year":"2015","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.prp.2023.154632_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2020.00257","article-title":"TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens","volume":"11","author":"Akatsuka","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2023.154632_bib34","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.3390\/curroncol28050316","article-title":"Designing inclusive HPV cancer vaccines and increasing uptake among native americans-a cultural perspective review","volume":"28","author":"Bordeaux","year":"2021","journal-title":"Curr. Oncol. (Tor., Ont. )"},{"issue":"8","key":"10.1016\/j.prp.2023.154632_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181844","article-title":"Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles","volume":"12","author":"Doucet","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The Next Immune-Checkpoint Inhibitors: PD-1\/PD-L1 Blockade in Melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40291-017-0308-6","article-title":"PD-L1 Testing in Guiding Patient Selection for PD-1\/PD-L1 Inhibitor Therapy in Lung Cancer","volume":"22","author":"Ancevski Hunter","year":"2018","journal-title":"Mol. Diagn. Ther."},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Xin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prp.2023.154632_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","article-title":"A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: The future is now","volume":"54","author":"Bellmunt","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2023.154632_bib41","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2147\/DDDT.S140687","article-title":"Inhibitors of the PD-1\/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives","volume":"11","author":"Ran","year":"2017","journal-title":"Drug Des., Dev. Ther."},{"key":"10.1016\/j.prp.2023.154632_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.prp.2023.154632_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.prp.2023.154632_bib44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/intimm\/dxab052","article-title":"Engineering strategies for broad application of TCR-T-and CAR-T-cell therapies","volume":"33","author":"Watanabe","year":"2021","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2023.154632_bib45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. The","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.prp.2023.154632_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"11","key":"10.1016\/j.prp.2023.154632_bib47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","article-title":"Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia","volume":"53","author":"Liu","year":"2017","journal-title":"Drugs of Today (Barcelona, Spain: 1998)"},{"issue":"2","key":"10.1016\/j.prp.2023.154632_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","article-title":"Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review","volume":"6","author":"Locke","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib50","first-page":"11","article-title":"Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood","volume":"140","author":"Frey","year":"2022","journal-title":"J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma\u2010cel) CD19 CAR\u2010T therapy for adults with heavily pretreated relapsed\/refractory large B\u2010cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib52","first-page":"107","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J. Immunother. (Hagerstown, Md: 1997)"},{"key":"10.1016\/j.prp.2023.154632_bib53","article-title":"KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma","author":"Usmani","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"10.1016\/j.prp.2023.154632_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2023.154632_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14760584.2022.2012456","article-title":"Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy","volume":"21","author":"Richard","year":"2022","journal-title":"Expert Rev. Vaccin."},{"issue":"2","key":"10.1016\/j.prp.2023.154632_bib56","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2023.154632_bib58","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/annonc\/mdw041","article-title":"Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies","volume":"27","author":"Sanmamed","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.prp.2023.154632_bib59","first-page":"S447","article-title":"Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what\u2019s known and what\u2019s next. Translational Lung","volume":"8","author":"Jiang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154632_bib60","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1038\/s41598-018-25482-w","article-title":"Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity","volume":"8","author":"Crittenden","year":"2018","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.prp.2023.154632_bib61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2023.154632_bib62","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-16-2379","article-title":"Intrinsic resistance of solid tumors to immune checkpoint blockade therapyresistance to immune checkpoint blockade therapy","volume":"77","author":"Zhao","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154632_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.prp.2023.154632_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2016.11.007","article-title":"Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer","volume":"599","author":"Lee","year":"2017","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-023-09058-7","article-title":"Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma","volume":"23","author":"Li","year":"2023","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib67","first-page":"1","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother. (Hagerstown, Md: 1997)"},{"issue":"11","key":"10.1016\/j.prp.2023.154632_bib68","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation\u2014how, and when? Data from melanoma as a paradigm","volume":"17","author":"Robert","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154632_bib69","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154632_bib70","first-page":"311","article-title":"Corrigendum: current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.prp.2023.154632_bib71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/rme-2016-0010","article-title":"Gene therapies: the challenge of super-high-cost treatments and how to pay for them","volume":"11","author":"Carr","year":"2016","journal-title":"Regen. Med."},{"key":"10.1016\/j.prp.2023.154632_bib72","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2019.00264","article-title":"Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis","volume":"9","author":"Addeo","year":"2019","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.prp.2023.154632_bib73","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.jmb.2018.05.030","article-title":"Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer","volume":"430","author":"Borcherding","year":"2018","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.prp.2023.154632_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238536","article-title":"Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: a systematic review","volume":"15","author":"Ding","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J. Immunol. Methods"},{"issue":"7","key":"10.1016\/j.prp.2023.154632_bib76","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6230","key":"10.1016\/j.prp.2023.154632_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.prp.2023.154632_bib78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2023.154632_bib79","series-title":"Medicine, ZPM, in Germany. Seminars in Cancer Biology","article-title":"Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized","year":"2022"},{"key":"10.1016\/j.prp.2023.154632_bib80","first-page":"169","article-title":"Genomic medicine, precision medicine, personalized medicine: what's in a name?","author":"Roden","year":"2013","journal-title":"Wiley Online Libr."},{"key":"10.1016\/j.prp.2023.154632_bib81","first-page":"59","article-title":"Personalized medicine in breast cancer: pharmacogenomics approaches","author":"Jeibouei","year":"2019","journal-title":"Pharm. Pers. Med."},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/jpm11030237","article-title":"Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer","volume":"11","author":"Ferro","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.prp.2023.154632_bib83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-030-16391-4_11","article-title":"Artificial intelligence and personalized medicine","author":"Schork","year":"2019","journal-title":"Precis. Med. Cancer Ther."},{"key":"10.1016\/j.prp.2023.154632_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104365","article-title":"Precision nutrition: A systematic literature review","volume":"133","author":"Kirk","year":"2021","journal-title":"Comput. Biol. Med."},{"issue":"2","key":"10.1016\/j.prp.2023.154632_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bulcan.2018.08.007","article-title":"Why is immunotherapy effective (or not) in patients with MSI\/MMRD tumors?","volume":"106","author":"Nebot-Bral","year":"2019","journal-title":"Bull. du Cancer"},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-019-0929-4","article-title":"Tumor mutation burden: from comprehensive mutational screening to the clinic","volume":"19","author":"Galuppini","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2023.154632_bib87","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fmolb.2020.00154","article-title":"Current state of target treatment in BRAF mutated melanoma","volume":"7","author":"Tanda","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.prp.2023.154632_bib88","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.3389\/fonc.2021.774577","article-title":"In real life, low-level HER2 expression may Be associated with better outcome in HER2-negative breast cancer: a study of the national cancer center, China","volume":"11","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2023.154632_bib89","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.prp.2023.154632_bib90","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2023.154632_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Drean","year":"2016","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.prp.2023.154632_bib92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2017.05.029","article-title":"Combined radiation therapy and immune checkpoint blockade therapy for breast cancer","volume":"99","author":"Hu","year":"2017","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"key":"10.1016\/j.prp.2023.154632_bib93","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h [A30P] \u03b1-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol. Dis."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823003321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823003321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:57:03Z","timestamp":1774411023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823003321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":93,"alternative-id":["S0344033823003321"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154632","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New immunotherapeutic approaches for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154632"}}